Why the study?
M-TEER improves outcomes in secondary mitral regurgitation with reduced LVEF, but evidence in patients with preserved LVEF remains limited.
Does mitral transcatheter edge-to-edge repair improve clinical outcomes in patients with symptomatic secondary mitral regurgitation?
Population
93 consecutive patients with symptomatic SMR treated with M-TEER
Comparison
Stratified by LVEF (<50% vs ≥50%) and LAVI (<60 vs ≥60 mL/m2)
Design
Retrospective cohort study
Follow-up
36 months
Key result
Mitral transcatheter edge-to-edge repair yielded similar 36-month clinical improvement in patients with preserved versus reduced LVEF (62.5% vs 51.8%, p=0.32).
Authors
Loading...
Similar improvement across LVEF after M-TEER is hypothesis-generating; leaves open randomized confirmation in preserved LVEF.
Cohort (n=93)
Does mitral transcatheter edge-to-edge repair improve clinical outcomes in patients with symptomatic secondary mitral regurgitation?
Absolute Event Rate: 62.5% vs 51.8%
p-value: p=0.32
M-TEER provides sustained clinical benefit in symptomatic secondary mitral regurgitation across the LVEF spectrum, with left atrial enlargement identifying patients at higher mortality risk.
Rouleau et al. (2026) conducted a cohort in Symptomatic secondary mitral regurgitation (n=93). Mitral transcatheter edge-to-edge repair (M-TEER) in preserved LVEF (≥50%) vs. M-TEER in reduced LVEF (<50%) was evaluated on Comprehensive clinical improvement at 36 months (survival without heart-failure hospitalization, NYHA class I–II, and KCCQ score >60) (p=0.32). Mitral transcatheter edge-to-edge repair yielded similar 36-month clinical improvement in patients with preserved versus reduced LVEF (62.5% vs 51.8%, p=0.32).